


I. Amendments to the Claims:

This listing of claims replaces without prejudice all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Currently amended) A method of inhibiting secretion of vascular endothelial growth factor in an animal in need of such inhibition, comprising administering to the animal an effective amount of a compound of Formula I, or a salt, ~~solvate, or hydrate~~ thereof:



wherein

R^1 and R^2 are each independently selected from H, OH, C_{1-6} alkyl, C_{1-6} alkoxy, NH_2 , $NH-C_{1-6}$ alkyl, $N(C_{1-6}alkyl)(C_{1-6}alkyl)$, SH, $S-C_{1-6}alkyl$, $O-Si(C_{1-6}alkyl)(C_{1-6}alkyl)(C_{1-6}alkyl)$, NO_2 , CF_3 , OCF_3 and halo;

R^3 is selected from H, OH, C_{1-6} alkyl, C_{1-6} alkoxy, NH_2 , $NH-C_{1-6}alkyl$, $N(C_{1-6}alkyl)(C_{1-6}alkyl)$, SH, $S-C_{1-6}alkyl$, $O-Si(C_{1-6}alkyl)(C_{1-6}alkyl)(C_{1-6}alkyl)$, NO_2 , halo and $CH_2-S-(CH_2)_n Ar$;

R^4 is selected from $C(X)R^5$, SO_3Ar , NH_2 , $NH-C_{1-6}alkyl$, $N(C_{1-6}alkyl)(C_{1-6}alkyl)$, $P(O)(OH)_2$, $P(O)(OC_{1-6}alkyl)_2$, and $C(NH_2)=C(CN)_2$;

X is selected from O, S, NH and $N-C_{1-6}alkyl$;


R^5 is selected from NH_2 , OH, $NH(CH_2)_p Ar$, $NH(CH_2)_p OH$, $(CH_2)_p OC_{1-6}alkyl$, $C_{1-6}alkyl$, $C_{1-6}alkoxy$, $NHNH_2$, $NHC(O)NH_2$, $NHC(O)C_{1-6}alkoxy$, N-morpholino and N-pyrrolidino; and

Ar is an aromatic or heteroaromatic group, unsubstituted or substituted with 1-4 substituents, independently selected from OH, $C_{1-6}alkyl$, $C_{1-6}alkoxy$, NH_2 , $NH-C_{1-6}alkyl$, $N(C_{1-6}alkyl)(C_{1-6}alkyl)$, SH, $S-C_{1-6}alkyl$, NO_2 , CF_3 , OCF_3 and halo;

n is 0 to 4; and

p is 1-4.

2. (Withdrawn)
3. (Withdrawn)
4. (Currently amended) A method of inhibiting an effect of vascular endothelial growth factor in an animal in need of such inhibition, comprising administering to the animal an effective amount of a compound of Formula I, or a salt, ~~solvate, or hydrate~~ thereof:



I

wherein

R¹ and R² are each independently selected from H, OH, C₁₋₆alkyl, C₁₋₆alkoxy, NH₂, NH-C₁₋₆alkyl, N(C₁₋₆alkyl)(C₁₋₆alkyl), SH, S-C₁₋₆alkyl, O-Si(C₁₋₆alkyl)(C₁₋₆alkyl)(C₁₋₆alkyl), NO₂, CF₃, OCF₃ and halo;

R³ is selected from H, OH, C₁₋₆alkyl, C₁₋₆alkoxy, NH₂, NH-C₁₋₆alkyl, N(C₁₋₆alkyl)(C₁₋₆alkyl), SH, S-C₁₋₆alkyl, O-Si(C₁₋₆alkyl)(C₁₋₆alkyl)(C₁₋₆alkyl), NO₂, halo and CH₂-S-(CH₂)_n Ar;

R⁴ is selected from C(X)R⁵, SO₃Ar, NH₂, NH-C₁₋₆alkyl, N(C₁₋₆alkyl)(C₁₋₆alkyl), P(O)(OH)₂, P(O)(OC₁₋₆alkyl)₂, and C(NH₂)=C(CN)₂;

X is selected from O, S, NH and N-C₁₋₆alkyl;

R⁵ is selected from NH₂, OH, NH(CH₂)_pAr, NH(CH₂)_pOH, (CH₂)_pOC₁₋₆alkyl, C₁₋₆alkyl, C₁₋₆alkoxy, NHNH₂, NHC(O)NH₂, NHC(O)C₁₋₆alkoxy, N-morpholino and N-pyrrolidino; and

Ar is an aromatic or heteroaromatic group, unsubstituted or substituted with 1-4 substituents, independently selected from OH, C₁₋₆alkyl, C₁₋₆alkoxy, NH₂, NH-C₁₋₆alkyl, N(C₁₋₆alkyl)(C₁₋₆alkyl), SH, S-C₁₋₆alkyl, NO₂, CF₃, OCF₃ and halo;

n is 0 to 4; and

p is 1-4.

5. (Withdrawn)
6. (Withdrawn)
7. (Previously amended) The method of claim 4, wherein the effect of vascular endothelial growth factor is angiogenesis, vasculogenesis, arteriogenesis, vascular permeability or inflammation.
8. (Cancelled)
9. (Withdrawn)
10. (Withdrawn)
- 11-16 (Cancelled)
- 17-46. (Cancelled)
47. (Withdrawn)
- 48-52 (Cancelled)
- 53-56. (Withdrawn)
57. (Cancelled)
- 58 (Currently Amended) The method of claim ~~57~~ 1, further comprising administering to said animal a therapeutically effective amount of at least a second anti-cancer agent.

59. (Original) The method of claim 58, wherein said at least a second anti-cancer agent is a chemotherapeutic agent, radiotherapeutic agent, anti-angiogenic agent, apoptosis-inducing agent or anti-tubulin drug or a tumor-targeted chemotherapeutic agent, radiotherapeutic agent, anti-angiogenic agent, apoptosis-inducing agent or anti-tubulin drug.
60. (Original) The method of claim 59, wherein said at least a second anti-cancer agent is an anti tubulin drug selected from the group consisting of colchicine, taxol, vinblastine, vincristine, vindesine and a combretastatin or a tumor-targeted anti-tubulin drug selected from the group consisting of colchicine, taxol, vinblastine, vincristine, vindesine and a combretastatin.
- 61-64. (Withdrawn)
65. (Cancelled)
- 66-68. (Withdrawn)
69. (Cancelled)